Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Michigan
Clinical trial register · United States · industry-sponsored

Clinical Trials in Michigan, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9148 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 21 Nov 2026, 03:16 UTC
9148
Studies in scope
industry-sponsored, all four open statuses
4975
Recruiting now
open to new participants
2181
Lead sponsors
across recruiting studies
Top states
California 5328 Florida 4488 Illinois 2493 Georgia 2364 Arizona 2269

Trials with a site in Michigan

1476 of 9148 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Safety Study of XT-150 in Participants With ALS
NCT06704347Amyotrophic Lateral Sclerosis (ALS)
Xalud Therapeutics, Inc.
Phase 1
8
Arizona, Maryland, Massachusetts, Michigan
2027-03
Not yet open
United Therapeutics
Phase 2/3
400
Arizona, California, Illinois, Kentucky, Massachusetts, Michigan, North Carolina, Pennsylvania
2027-03
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Arizona, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2027-02-03
Not yet open
Boehringer Ingelheim
Phase 3
270
Arizona, California, Colorado, Illinois, Kansas, Maryland, Massachusetts, Michigan
2026-12-14
Not yet open
Long Term Safety Study in Patients With HLH/MAS in Still's Disease Exposed to Gamifant.
NCT07909005Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS), Still Disease
Swedish Orphan Biovitrum
Observational
70
Alabama, California, Florida, Georgia, Massachusetts, Michigan, Minnesota, New York
2026-12
Not yet open
Sun Pharma Advanced Research Company Limited
Phase 4
45
Michigan
2026-12
Not yet open
Boehringer Ingelheim
Phase 3
600
Arizona, California, Colorado, Florida, Kansas, Maryland, Massachusetts, Michigan
2026-11-25
Not yet open
A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
NCT07897721Advanced Breast Cancer, Advanced or Metastatic Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Metastatic Colorectal Adenocarcinoma
Pfizer
Phase 1
268
Arkansas, Michigan
2026-11-09
Recruiting
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
NCT07903415Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma
Pfizer
Phase 1
280
Michigan, Tennessee, Texas
2026-11-05
Recruiting
argenx
Phase 2
120
California, Florida, Michigan, Texas, Utah, Virginia
2026-11-05
Not yet open
R-2487 in Patients With Sjogren's Syndrome (SjD)
NCT06297213Sjogren's Syndrome, Sjögren, Sjögren Syndrome, Unspecified
Rise Therapeutics LLC
Phase 1
36
Maryland, Michigan
2026-11-01
Recruiting
TG Therapeutics, Inc.
Phase 2
120
Colorado, Florida, Michigan, North Carolina, South Carolina
2026-11-01
Not yet open
United Therapeutics
Phase 2
40
Alabama, Arizona, California, Illinois, Kentucky, Massachusetts, Michigan, North Carolina
2026-11
Recruiting
AFT Pharmaceuticals, Ltd.
Phase 3
1,366
Arizona, Florida, Indiana, Michigan, New York, North Carolina, South Carolina, Texas
2026-11
Not yet open
Hummingbird ICE Study
NCT07552272ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION, Atrial Fibrillation (AF), Valve Disease, Heart, Atrial Septal Defect
Philips Clinical & Medical Affairs Global
Observational
1,000
Michigan, New Jersey
2026-11
Not yet open
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
NCT07873931Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
Bristol-Myers Squibb
Phase 1
60
California, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New York, Pennsylvania
2026-10-30
Recruiting
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
NCT07473700Hypertension, Pulmonary, Lung Diseases, Interstitial
Tectonic Operating Company, Inc.
Phase 2
25
Arizona, California, Idaho, Michigan
2026-10-30
Recruiting
JUR-003 in Adult Patients With Metastatic Prostate Cancer
NCT07824349Metastatic Castration Resistant Prostate Cancer, Oligometastatic Prostate Cancer (OMPC), Metastatic Hormone Sensitive Prostate Cancer
Juri Biosciences, Inc.
Phase 1
210
Michigan, New York, Tennessee, Texas
2026-10-26
Not yet open
Alembic Therapeutics
Phase 2
100
Michigan
2026-10-24
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
404
Michigan
2026-10-22
Recruiting
Sagimet Biosciences Inc.
Phase 3
800
Arkansas, California, Florida, Illinois, Indiana, Massachusetts, Michigan, Missouri
2026-10-21
Recruiting
TerSera Therapeutics LLC
Phase 1
176
Arkansas, District of Columbia, Florida, Georgia, Illinois, Iowa, Louisiana, Michigan
2026-10-20
Recruiting
Viridian Therapeutics, Inc.
Phase 4
30
California, Florida, Massachusetts, Michigan, Missouri, New Jersey, Texas
2026-10-19
Not yet open
Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC
NCT07870746ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 2
40
California, Florida, Michigan, Ohio, Pennsylvania, Wisconsin
2026-10-15
Recruiting
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
NCT07787182Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Eli Lilly and Company
Phase 1
68
California, Florida, Georgia, Michigan
2026-10-10
Recruiting
argenx
Phase 2
75
Florida, Michigan
2026-10-09
Recruiting
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
NCT07843459Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Eli Lilly and Company
Phase 1
111
California, Florida, Georgia, Michigan
2026-10-07
Recruiting
Novartis Pharmaceuticals
Phase 3
180
California, Florida, Georgia, Massachusetts, Michigan, Ohio, Texas
2026-10-07
Recruiting
Bristol-Myers Squibb
Phase 3
176
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2026-10-06
Recruiting
Hoffmann-La Roche
Phase 3
400
California, Florida, Georgia, Massachusetts, Michigan, Nevada, New Mexico, Ohio
2026-10-06
Recruiting
GE Healthcare
Phase 2/3
175
Michigan
2026-10
Recruiting
PRG Science & Technology Co., Ltd.
Phase 2
5
Michigan
2026-10
Recruiting
Ray Therapeutics, Inc.
Phase 2/3
60
Arizona, California, Florida, Hawaii, Illinois, Michigan, Minnesota, New Jersey
2026-10
Recruiting
Trevi Therapeutics
Phase 3
201
Alabama, Connecticut, Delaware, Florida, Maryland, Michigan, Missouri, North Carolina
2026-09-30
Recruiting
Lantheus Medical Imaging
Phase 2/3
408
Michigan
2026-09-30
Recruiting
Pfizer
Phase 3
660
Alabama, California, Florida, Indiana, Kentucky, Michigan, Mississippi, Missouri
2026-09-30
Recruiting
Novartis Pharmaceuticals
Phase 2
259
Alabama, California, Florida, Georgia, Indiana, Kansas, Louisiana, Michigan
2026-09-29
Recruiting
A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC
NCT07725796Bladder (Urothelial, Transitional Cell) Cancer, NMIBC, Urothelial Carcinoma Bladder, Urothelial Carcinoma in Situ
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
Phase 1
30
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Nebraska, New York
2026-09-28
Recruiting
Charm Therapeutics
Phase 1
40
California, Connecticut, Michigan, New York, Tennessee
2026-09-28
Recruiting
Acurx Pharmaceuticals Inc.
Phase 2
20
California, Connecticut, Florida, Georgia, Idaho, Illinois, Massachusetts, Michigan
2026-09-25
Recruiting
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
AstraZeneca
Phase 3
600
Alaska, Florida, Indiana, Louisiana, Maryland, Michigan, New York, Ohio
2026-09-24
Recruiting
Akeso
Phase 3
900
Arizona, California, Colorado, Connecticut, Massachusetts, Michigan, New York, Oregon
2026-09-24
Recruiting
Orum Therapeutics USA, Inc.
Phase 1
42
Michigan, Texas
2026-09-23
Recruiting
Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test
NCT07859852Blood Stream Infection, Blood Stream Infections, Sepsis, Fungemia
Deepull Diagnostics S.L.
Observational
1,500
California, Florida, Maryland, Massachusetts, Michigan, Missouri, Ohio, Pennsylvania
2026-09-21
Recruiting
Boehringer Ingelheim
Phase 3
466
Alabama, California, Connecticut, Florida, Indiana, Kansas, Michigan, Minnesota
2026-09-17
Recruiting
Pfizer
Phase 3
258
Alabama, Arkansas, California, Florida, Michigan, Minnesota, Texas
2026-09-17
Recruiting
Vima Therapeutics
Phase 2
80
Arizona, California, Connecticut, Florida, Georgia, Kansas, Maryland, Michigan
2026-09-15
Recruiting
AstraZeneca
Phase 3
1,330
Arkansas, California, Florida, Hawaii, Illinois, Iowa, Maryland, Michigan
2026-09-15
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors
NCT07807956Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
AbbVie
Phase 1
130
Michigan, North Carolina, Texas
2026-09-14
Recruiting
Vividion Therapeutics, Inc.
Phase 2
140
Arizona, Michigan, West Virginia
2026-09-11
Recruiting
Takeda
Phase 3
324
Arizona, California, District of Columbia, Florida, Georgia, Massachusetts, Michigan, Missouri
2026-09-10
Recruiting
Triveni Bio
Phase 2
90
California, Florida, Indiana, Michigan, Ohio, Pennsylvania, South Carolina, Texas
2026-09-09
Recruiting
Eli Lilly and Company
Phase 1
179
California, Florida, Georgia, Michigan
2026-09-09
Recruiting
IDEAYA Biosciences
Phase 3
450
Arizona, California, Florida, Massachusetts, Michigan, New York, North Carolina, Ohio
2026-09-04
Recruiting
ModernaTX, Inc.
Phase 2
300
California, Florida, Illinois, Michigan, Ohio, Texas, Utah, Virginia
2026-09-04
Recruiting
Orphalan
Phase 3
38
Colorado, Connecticut, Michigan
2026-09-03
Not yet open
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
NCT07781852Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
Lumina Pharmaceuticals Inc
Early Phase 1
40
Massachusetts, Michigan, New York
2026-09-01
Recruiting
Bayer
Phase 2
360
California, Colorado, Massachusetts, Michigan, Minnesota, North Carolina, Texas
2026-09-01
Recruiting
Geneos Therapeutics
Phase 2
90
Georgia, Louisiana, Maryland, Michigan, New York, Texas, Washington
2026-09
Recruiting
Recursion Pharmaceuticals Inc.
Phase 1/2
90
Michigan, Texas, Virginia
2026-09
Recruiting
MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee
NCT07332182Osteochondral Lesions of the Knee Joint, Osteochondritis Dissecans (OCD), Early Osteoarthritis
Fin-Ceramica Faenza Spa
Not applicable
400
California, Colorado, Illinois, Michigan, Ohio, Oregon, Tennessee, Texas
2026-09
Not yet open
New Functional Ingredient for Oral Care
NCT07771907Oral Health Related Quality of Life (OHRQoL)
Access Business Group
Not applicable
100
Michigan
2026-09
Recruiting
AstraZeneca
Phase 3
1,072
Arizona, California, Florida, Illinois, Indiana, Maryland, Massachusetts, Michigan
2026-08-31
Recruiting
Amgen
Phase 3
400
Florida, Michigan, Nebraska
2026-08-28
Recruiting
GlaxoSmithKline
Phase 3
370
California, Florida, Michigan, New Mexico, Pennsylvania, Texas
2026-08-27
Recruiting
Pfizer
Phase 3
400
Arizona, California, Florida, Georgia, Indiana, Kansas, Massachusetts, Michigan
2026-08-26
Recruiting
Genentech, Inc.
Phase 3
300
Alabama, California, Connecticut, District of Columbia, Michigan, Nevada, New Jersey, New Mexico
2026-08-25
Recruiting
Oruka Therapeutics, Inc.
Phase 2
200
Alabama, California, Connecticut, Georgia, Illinois, Indiana, Louisiana, Michigan
2026-08-21
Recruiting
Pulnovo Medical, Inc.
Not applicable
750
Arizona, Connecticut, District of Columbia, Florida, Louisiana, Massachusetts, Michigan, New York
2026-08-21
Recruiting
Pfizer
Phase 3
1,100
California, Florida, Maryland, Michigan, New Jersey, North Carolina, Oklahoma, Tennessee
2026-08-20
Recruiting
VarmX B.V.
Phase 3
800
Arizona, California, Colorado, Delaware, Florida, Iowa, Massachusetts, Michigan
2026-08-18
Recruiting
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
NCT07745361Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma)
Monte Rosa Therapeutics, Inc
Phase 2
25
California, Colorado, Kansas, Maryland, Michigan, Nebraska, New Jersey, North Carolina
2026-08-18
Recruiting
Alkermes, Inc.
Phase 3
150
Arizona, Florida, Georgia, Kansas, Michigan, Minnesota, Missouri, New York
2026-08-13
Recruiting
A Study of LY3971297 in Participants With Heart Failure
NCT07547540Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic
Eli Lilly and Company
Phase 1
90
Michigan, Missouri, North Carolina, Texas
2026-08-11
Recruiting
Alveus Therapeutics, Inc.
Phase 2
220
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Michigan
2026-08-10
Recruiting
Alkermes, Inc.
Phase 2
312
Arkansas, California, Florida, Georgia, Massachusetts, Michigan, Nebraska, Nevada
2026-08-10
Recruiting
Eli Lilly and Company
Phase 2
606
Alabama, California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan
2026-08-07
Recruiting
Janssen Research & Development, LLC
Phase 1
160
Florida, Michigan, New York, Utah
2026-08-05
Recruiting
Sling Therapeutics, Inc.
Phase 3
130
Arizona, California, Florida, Massachusetts, Michigan, Nevada, New Jersey, New York
2026-08-04
Recruiting
Novo Nordisk A/S
Phase 3
80
Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Michigan, New York
2026-08-04
Recruiting
ORIC Pharmaceuticals
Phase 3
600
California, Florida, Indiana, Michigan, North Carolina, Ohio, Pennsylvania, South Carolina
2026-08-03
Recruiting
VectivBio AG
Phase 3
124
California, Colorado, District of Columbia, Florida, Illinois, Kentucky, Michigan, New York
2026-08
Recruiting
Pfizer
Phase 3
336
California, Florida, Illinois, Indiana, Iowa, Maryland, Massachusetts, Michigan
2026-07-30
Recruiting
VelaVigo Bio Inc
Phase 1/2
230
California, Michigan, New York, Texas, Virginia
2026-07-30
Not yet open
Evopoint Biosciences Inc.
Phase 1
24
Michigan, New York, Ohio, Oklahoma, Tennessee, Texas
2026-07-30
Recruiting
Evommune, Inc.
Phase 2
330
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2026-07-29
Recruiting
Verastem, Inc.
Phase 2
150
Arizona, California, Florida, Indiana, Michigan, Missouri, New Jersey, New York
2026-07-28
Recruiting
H. Lundbeck A/S
Phase 2
150
Florida, Michigan, Texas
2026-07-28
Recruiting
VDyne, Inc.
Not applicable
520
Arizona, California, Kansas, Michigan, Minnesota, Ohio, Oregon, South Carolina
2026-07-28
Recruiting
Bristol-Myers Squibb
Phase 2
254
California, Colorado, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New York
2026-07-27
Active, closed
Autus Valve Continued Access Study (CAS)
NCT07466745Congenital Heart Disease
Edwards Lifesciences
Not applicable
4
Michigan
2026-07-27
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
AstraZeneca
Phase 3
230
Colorado, Maryland, Michigan, New Jersey, New York, North Carolina, Ohio, Utah
2026-07-24
Recruiting
CathVision ApS
Observational
40
Michigan, New Jersey
2026-07-22
Recruiting
Agios Pharmaceuticals, Inc.
Phase 3
159
Indiana, Michigan, Mississippi, New York, Texas
2026-07-21
Recruiting
Gilead Sciences
Phase 1
302
Michigan, Texas
2026-07-17
Recruiting
DBC-664 in Adult Patients With Solid Tumors
NCT07705035Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
Duboce Biopharmaceuticals, Inc.
Phase 1
210
Colorado, Michigan, Missouri, New Jersey, New York, Tennessee, Texas
2026-07-17
Recruiting
Novartis Pharmaceuticals
Phase 3
570
Arizona, Arkansas, California, Florida, Illinois, Massachusetts, Michigan, New Jersey
2026-07-16
Recruiting
A Trial of CRD-4730 in HFrEF
NCT07750873Heart Failure With Reduced Ejection Fraction (HFrEF)
Cardurion Pharmaceuticals, Inc.
Phase 2
525
California, Michigan
2026-07-15
Recruiting
Gilead Sciences
Phase 3
850
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Michigan, Missouri
2026-07-14
Recruiting
Immunomic Therapeutics, Inc.
Phase 1
60
California, Michigan, Tennessee, Texas
2026-07-14
Recruiting
Medtronic Neurovascular Clinical Affairs
Observational
1,500
Michigan, New York, Texas
2026-07-13
Recruiting
Novartis Pharmaceuticals
Phase 3
710
Alabama, Arkansas, California, Florida, Illinois, Indiana, Michigan, Nebraska
2026-07-10
Recruiting
Jazz Pharmaceuticals
Phase 3
120
Alabama, California, Colorado, Delaware, Florida, Georgia, Maryland, Michigan
2026-07-09
Recruiting
DePuy Synthes Products, Inc.
Observational
100
Iowa, Michigan, North Carolina, Virginia
2026-07-07
Recruiting
AstraZeneca
Phase 3
900
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2026-07-06
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
134
California, Colorado, Florida, Iowa, Massachusetts, Michigan, Missouri, New Jersey
2026-07-06
Recruiting
Nyra Medical, Inc.
Not applicable
30
California, Michigan, Ohio
2026-07-02
Recruiting
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07719361Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms
Flare Therapeutics Inc.
Phase 1
60
California, Massachusetts, Michigan, New Jersey, South Carolina, Tennessee, Texas
2026-07-01
Recruiting
Neurocrine Switzerland GmbH
Phase 2
20
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Michigan, Minnesota
2026-07-01
Recruiting
A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
NCT07664735Endometrial Cancer Recurrent, Endometrial Cancer, Advanced Endometrial Cancer, Ovarian Cancer
Outpace Bio, Inc.
Phase 1
30
California, Georgia, Michigan, Minnesota, Texas
2026-06-30
Recruiting
Hillhurst Biopharmaceuticals, Inc.
Phase 2
36
California, Florida, Massachusetts, Michigan, New York, Washington
2026-06-30
Recruiting
Merck Sharp & Dohme LLC
Phase 2
750
Alabama, California, Connecticut, Florida, Maryland, Michigan, Minnesota, Montana
2026-06-30
Active, closed
Boehringer Ingelheim
Phase 2
345
Alabama, California, Florida, Georgia, Kentucky, Michigan, Missouri, North Carolina
2026-06-30
Recruiting
ITB-Med LLC
Phase 2
120
California, Florida, Georgia, Kansas, Kentucky, Louisiana, Massachusetts, Michigan
2026-06-29
Recruiting
Cordis US Corp.
Observational
35
California, Georgia, Michigan, Missouri, Nebraska, Ohio, Pennsylvania, Texas
2026-06-23
Recruiting
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
NCT07406633GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer, Gastro Intestinal Stromal Tumour
Kumquat Biosciences Inc.
Phase 2
46
California, Florida, Illinois, Iowa, Massachusetts, Michigan, Minnesota, New York
2026-06-23
Recruiting
Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension
NCT07511361Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
Kardigan, Inc.
Phase 2
140
Colorado, Florida, Illinois, Michigan, New York, Ohio, South Carolina, Tennessee
2026-06-23
Recruiting
Shockwave Medical, Inc.
Not applicable
185
Arkansas, California, District of Columbia, Florida, Illinois, Massachusetts, Michigan, Minnesota
2026-06-22
Recruiting
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07581184Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC
Aktis Oncology, Inc.
Phase 1
138
California, Florida, Kansas, Louisiana, Massachusetts, Michigan, Nebraska, Pennsylvania
2026-06-17
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
Verastem, Inc.
Phase 2
185
California, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2026-06-16
Recruiting
Nuevocor Pte. Ltd.
Phase 1/2
21
Alabama, California, Massachusetts, Michigan, Minnesota, Ohio, Texas
2026-06-16
Recruiting
Gilead Sciences
Phase 2
175
Arizona, California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey
2026-06-15
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
Takeda
Phase 2/3
500
California, Colorado, Florida, Georgia, Maryland, Michigan, Missouri, New Jersey
2026-06-11
Recruiting
argenx
Phase 3
230
California, Florida, Kansas, Michigan, Missouri, New York, North Carolina, Texas
2026-06-10
Recruiting
Yarrow Bioscience, Inc.
Phase 2
232
Arizona, California, Florida, Georgia, Kentucky, Michigan, Nebraska, New York
2026-06-10
Recruiting
Pfizer
Phase 3
954
California, Florida, Illinois, Indiana, Kentucky, Maryland, Michigan, Nebraska
2026-06-10
Recruiting
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
NCT07504458Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Quetzal Therapeutics
Phase 3
150
Alabama, California, Colorado, Georgia, Kentucky, Maryland, Michigan, New York
2026-06-08
Recruiting
Genentech, Inc.
Phase 2
162
California, Connecticut, Florida, Indiana, Michigan, Minnesota, Missouri, Nebraska
2026-06-05
Recruiting
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
NCT07629960Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Blueprint Medicines Corporation
Phase 1/2
265
Florida, Louisiana, Massachusetts, Michigan, New Jersey, New York, Tennessee, Texas
2026-06-04
Recruiting
Castle Biosciences Incorporated
Observational
450
Arizona, California, Florida, Maryland, Michigan, Missouri, Nevada, New Hampshire
2026-06-04
Recruiting
Alkeus Pharmaceuticals, Inc.
Phase 3
230
Arizona, Colorado, Florida, Massachusetts, Michigan, Ohio, Pennsylvania, Texas
2026-06-03
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
150
California, Florida, Massachusetts, Michigan, Missouri, New York, North Carolina, South Dakota
2026-06-02
Recruiting
Gilead Sciences
Phase 1
174
Massachusetts, Michigan, New Jersey, New York, Texas
2026-06-02
Recruiting
Bayer
Phase 3
117
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2026-06-01
Recruiting
Eli Lilly and Company
Phase 3
252
California, Florida, Idaho, Massachusetts, Michigan, Nevada, Pennsylvania, Utah
2026-06-01
Active, closed
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
NCT06712654Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
R1 Therapeutics
Phase 2
168
Alabama, California, Colorado, Connecticut, Florida, Georgia, Michigan, Minnesota
2026-06-01
Recruiting
Centessa Pharmaceuticals (UK) Limited
Phase 2/3
222
Alabama, Colorado, Florida, Georgia, Michigan, Mississippi, North Carolina, Ohio
2026-05-29
Recruiting
Pfizer
Phase 4
400
California, Florida, Illinois, Indiana, Kansas, Massachusetts, Michigan, Minnesota
2026-05-28
Recruiting
Oculis
Phase 3
210
Michigan, South Carolina, Texas
2026-05-28
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
California, Colorado, Connecticut, Illinois, Iowa, Kansas, Massachusetts, Michigan
2026-05-28
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals
Phase 3
460
Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Maryland, Michigan
2026-05-27
Recruiting
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
NCT07542704Advanced Solid Tumors, Colorectal Cancer (CRC), Non-Small Cell Lung Cancer, Uterine Cancer
Kumquat Biosciences Inc.
Phase 1
48
California, Massachusetts, Michigan, New Jersey, New York, Ohio, Oregon, Pennsylvania
2026-05-27
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
250
California, Florida, Georgia, Maryland, Michigan, New York, Ohio, Pennsylvania
2026-05-25
Recruiting
Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
NCT07599982Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
DreaMed Diabetes
Not applicable
102
Maryland, Michigan, New York, North Carolina, Texas, Utah
2026-05-25
Recruiting
Ionis Pharmaceuticals, Inc.
Phase 1/2
32
Michigan, Minnesota, North Carolina, Pennsylvania, Tennessee, Washington
2026-05-21
Recruiting
Regeneron Pharmaceuticals
Phase 3
270
Arizona, Georgia, Massachusetts, Michigan, Minnesota, Missouri, New York, Ohio
2026-05-21
Recruiting
Eli Lilly and Company
Phase 1
30
California, Florida, Michigan
2026-05-21
Recruiting
Hoffmann-La Roche
Phase 2/3
650
Alabama, Arizona, California, Connecticut, Michigan, New Jersey, New York, Tennessee
2026-05-21
Recruiting
Alpha Cognition, Inc
Phase 4
150
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2026-05-20
Active, closed
Novo Nordisk A/S
Phase 3
985
Florida, Georgia, Idaho, Maryland, Michigan, Texas, Virginia
2026-05-20
By invitation
ID-ENTITY Trial- Evaluating Serial T-ID Monitoring
NCT07393594Kidney Diseases, Kidney Injury, BK Virus Infection, CMV
Transplant Genomics, Inc.
Observational
1,000
Arizona, California, Kansas, Michigan, New Hampshire, New Jersey, New York, North Carolina
2026-05-19
Recruiting
Tissium
Not applicable
240
California, Florida, Illinois, Kentucky, Michigan, Nebraska, North Carolina, Ohio
2026-05-14
Recruiting
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
NCT07579702Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Insulet Corporation
Not applicable
200
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Massachusetts, Michigan
2026-05-13
Recruiting
Janssen Research & Development, LLC
Phase 1
320
Indiana, Michigan, New Jersey, New York, Tennessee, Texas
2026-05-13
Recruiting
A Study to Assess the Safety, Tolerability and Efficacy of ION775
NCT07604974Hypertriglyceridemia, Severe Hypertriglyceridemia
Ionis Pharmaceuticals, Inc.
Phase 2
72
California, Colorado, Florida, Georgia, Indiana, Kentucky, Michigan, Ohio
2026-05-12
Recruiting
CAPTURE-2: Controlled Arterial Protection to Ultimately Remove Embolic Material
NCT07276711Aortic Valve Stenosis, Aortic Stenosis, Aortic Valve Disease
EmStop Inc
Not applicable
663
California, Florida, Louisiana, Michigan, North Carolina, South Dakota, Texas
2026-05-12
Recruiting
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
NCT07296744Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support
Supira Medical
Not applicable
358
California, Florida, Georgia, Illinois, Michigan, Minnesota, Missouri, New Jersey
2026-05-11
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
390
Arkansas, California, Colorado, Delaware, Illinois, Indiana, Michigan, Missouri
2026-05-11
Recruiting
GlaxoSmithKline
Phase 3
1,209
Alabama, California, Florida, Georgia, Illinois, Michigan, Ohio, South Carolina
2026-05-11
Recruiting
J-Pharma Co., Ltd.
Phase 3
480
California, Florida, Illinois, Kentucky, Louisiana, Michigan, Minnesota, Nevada
2026-05-11
Recruiting
Genmab
Phase 2
160
California, Colorado, Florida, Michigan, Tennessee, Texas
2026-05-11
Recruiting
Eli Lilly and Company
Phase 2
531
Arizona, California, Florida, Illinois, Indiana, Kentucky, Michigan, Minnesota
2026-05-06
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
California, Colorado, Florida, Illinois, Michigan, Minnesota, Missouri, New York
2026-05-06
Recruiting
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Recruiting
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 1/2
150
Alabama, California, Florida, Georgia, Indiana, Michigan, Minnesota, New Hampshire
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
California, Colorado, Connecticut, Florida, Illinois, Michigan, Missouri, Montana
2026-05-04
Recruiting
LEO Pharma
Phase 3
552
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Illinois, Michigan
2026-05-01
Recruiting
Enlivex Therapeutics Ltd.
Phase 2
182
Florida, Louisiana, Michigan
2026-05-01
Recruiting
Kriya Therapeutics, Inc.
Phase 1/2
135
Michigan, Nevada, Pennsylvania
2026-05-01
Recruiting
Oncolytics Biotech
Phase 2
60
Alabama, California, Florida, Georgia, Idaho, Illinois, Indiana, Michigan
2026-04-30
Recruiting
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
NCT07469891Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis
Prelude Therapeutics Incorporated
Phase 1
100
California, Colorado, Florida, Michigan, Pennsylvania, Tennessee, Texas
2026-04-29
Recruiting
Hoffmann-La Roche
Phase 3
360
California, Colorado, Florida, Indiana, Iowa, Michigan, Minnesota, Texas
2026-04-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
California, Colorado, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Michigan
2026-04-23
Recruiting
Aurinia Pharmaceuticals Inc.
Phase 1/2
81
California, Florida, Illinois, Michigan, Texas
2026-04-22
Recruiting
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
NCT07489651Generalized Anxiety Disorder
DrugRE104
Reunion Neuroscience Inc
Phase 2
160
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Michigan
2026-04-20
Recruiting
Novo Nordisk A/S
Phase 3
400
California, Connecticut, Florida, Illinois, Kentucky, Michigan, Missouri, New York
2026-04-20
Recruiting
Boehringer Ingelheim
Phase 2
405
California, Colorado, Florida, Michigan, Mississippi, Montana, North Carolina, Ohio
2026-04-20
Recruiting
EVERO Drug-coated Balloon (DCB) Randomized Trial
NCT07144150Peripheral Vascular Disease, Peripheral Arterial Disease
Cook Research Incorporated
Not applicable
410
California, Connecticut, District of Columbia, Florida, Georgia, Indiana, Iowa, Michigan
2026-04-17
Recruiting
Blueprint Medicines Corporation
Observational
150
Colorado, Illinois, Maryland, Massachusetts, Michigan, Missouri, Utah
2026-04-15
Recruiting
Regeneron Pharmaceuticals
Phase 2
120
California, Florida, Georgia, Illinois, Kentucky, Michigan, Nebraska, New York
2026-04-14
Recruiting
Eli Lilly and Company
Phase 2
65
California, Florida, Massachusetts, Michigan, New Hampshire, Texas, Utah
2026-04-14
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
Eli Lilly and Company
Phase 2
66
Arizona, California, Florida, Georgia, Indiana, Massachusetts, Michigan, New Hampshire
2026-04-14
Recruiting
Boehringer Ingelheim
Phase 3
670
Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Maryland, Michigan
2026-04-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
California, Georgia, Kentucky, Massachusetts, Michigan, Missouri, New Jersey, New York
2026-04-09
Recruiting
Amgen
Phase 1
50
California, Maryland, Massachusetts, Michigan, Minnesota, New York, Pennsylvania, Texas
2026-04-08
Recruiting
Genmab
Phase 1
121
Connecticut, Michigan, New York
2026-04-07
Active, closed
Cochlear
Not applicable
56
Colorado, Florida, Iowa, Michigan, Minnesota, Missouri, New York, Ohio
2026-04-03
Recruiting
Biosense Webster, Inc.
Not applicable
566
Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Michigan, New Jersey
2026-04-02
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Arizona, Arkansas, California, Florida, Maryland, Michigan, Missouri, Nevada
2026-04-02
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
202
California, Florida, Indiana, Louisiana, Michigan, North Carolina, Texas
2026-04-01
Recruiting
Bausch Health Americas, Inc.
Phase 4
100
Arkansas, California, Florida, Kentucky, Michigan, Nevada, New York, North Carolina
2026-04-01
Not yet open
Cyllene Therapeutics
Phase 1/2
16
California, Michigan, Pennsylvania, Texas
2026-04
Recruiting
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
NCT07454642Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma
Avacta Life Sciences Ltd
Phase 1
174
Arizona, Florida, Illinois, Michigan, New York, Texas, Virginia
2026-03-31
Recruiting
MapLight Therapeutics
Phase 2
500
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2026-03-31
Recruiting
Vergent Bioscience, Inc.
Phase 3
132
California, Colorado, Florida, Michigan, Minnesota, Pennsylvania, Texas
2026-03-31
Recruiting
Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)
NCT07357428Amyotrophic Lateral Sclerosis, Neuromuscular Disease, Stroke, Tetraplegia/Tetraparesis
Paradromics
Not applicable
2
California, Massachusetts, Michigan
2026-03-31
Recruiting
Merck Sharp & Dohme LLC
Phase 1
40
Alabama, California, Colorado, Florida, Georgia, Illinois, Michigan, Minnesota
2026-03-30
By invitation
Aura Biosciences
Observational
100
California, Michigan, Minnesota, Oklahoma, South Carolina, Tennessee, Texas, Utah
2026-03-27
Recruiting
Eisai Inc.
Phase 2
64
California, Florida, Georgia, Maryland, Michigan, North Carolina, South Carolina, Texas
2026-03-26
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
California, Connecticut, District of Columbia, Florida, Indiana, Iowa, Maryland, Michigan
2026-03-26
Recruiting
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
NCT07144319Bladder Cancer, Non-muscle Invasive Bladder Cancer
Photocure
Observational
500
Florida, Iowa, Michigan, New Jersey, Tennessee
2026-03-25
Recruiting
Zenas BioPharma (USA), LLC
Phase 3
990
Arizona, California, Florida, Indiana, Kansas, Massachusetts, Michigan, Missouri
2026-03-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
450
Massachusetts, Michigan, Pennsylvania, Tennessee, Texas, Washington
2026-03-23
Recruiting
Boehringer Ingelheim
Phase 2
132
Alabama, California, Colorado, Florida, Illinois, Maryland, Michigan, New York
2026-03-23
Active, closed
Oruka Therapeutics, Inc.
Phase 2
160
Alabama, Arizona, California, Connecticut, Florida, Illinois, Massachusetts, Michigan
2026-03-19
Recruiting
BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System
NCT07118358Leadless Pacemaker, Bradycardia, AV Block, Cardiac Rhythm Disorder
Biotronik, Inc.
Not applicable
325
California, Colorado, Florida, Kentucky, Massachusetts, Michigan, Minnesota, Missouri
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 1/2
198
California, Illinois, Michigan, New Jersey, New York, Oregon, Tennessee, Washington
2026-03-16
Recruiting
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
NCT07470853PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
Whitehawk Therapeutics, Inc.
Phase 1
265
Arkansas, California, Florida, Illinois, Michigan, New York, North Carolina, Ohio
2026-03-15
Recruiting
Regeneron Pharmaceuticals
Phase 3
28
Michigan, Texas
2026-03-13
Recruiting
Sanofi
Phase 2/3
526
California, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan, New York
2026-03-13
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
Arkansas, California, Illinois, Indiana, Kansas, Michigan, Minnesota, New Jersey
2026-03-12
Recruiting
HeartFlow, Inc.
Observational
5,000
California, Florida, Georgia, Illinois, Kentucky, Michigan, Minnesota, New Jersey
2026-03-11
Recruiting
Continuity Biosciences, LLC
Phase 1
12
Michigan, West Virginia
2026-03-11
Active, closed
Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support (VR-CARES)
NCT07430371Direct Care Workers, Dementia Caregiver, In-Home Care, Caregiver Social Support
Rendever, Inc.
Not applicable
30
California, Massachusetts, Michigan, Texas
2026-03-11
Recruiting
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
NCT07457918Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
250
Florida, Indiana, Louisiana, Maryland, Michigan, Nebraska, Ohio, Oklahoma
2026-03-11
Recruiting
Takeda
Phase 3
1,182
Arizona, California, Colorado, Florida, Maryland, Michigan, North Carolina, Ohio
2026-03-11
Recruiting
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
NCT07424833Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Ascentage Pharma Group Inc.
Phase 1
180
California, Florida, Michigan, New Jersey, Texas
2026-03-10
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
EMD Serono Research & Development Institute, Inc.
Phase 3
202
California, Florida, Georgia, Michigan, Texas
2026-03-10
Recruiting
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
NCT07584226Advanced NRAS-Mutant Melanoma, Advanced NRAS-Mutant Solid Tumors, NRAS Mutation, NRAS G12D
Relay Therapeutics, Inc.
Phase 1/2
180
California, Colorado, Massachusetts, Michigan, New York, Tennessee, Virginia
2026-03-09
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Alabama, California, Florida, Illinois, Indiana, Maryland, Michigan, Nebraska
2026-03-09
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc.
Phase 3
900
Arizona, California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Nevada
2026-03-09
Recruiting
Thryv Therapeutics
Phase 2/3
84
Arizona, California, Illinois, Massachusetts, Michigan, Minnesota, New York, North Carolina
2026-03-07
Recruiting
Janssen Research & Development, LLC
Phase 3
600
California, Colorado, Florida, Georgia, Illinois, Louisiana, Michigan, New Jersey
2026-03-05
Recruiting
Janssen Research & Development, LLC
Phase 1
64
California, Georgia, Illinois, Michigan, New York, Texas
2026-03-02
Active, closed
Bactolife A/S
Observational
60
Georgia, Michigan, Minnesota, Wisconsin
2026-03-01
Recruiting
ASV Therapy for Insomnia
NCT07011966Insomnia, Insomnia (Moderate)
ResMed
Not applicable
25
Michigan
2026-03-01
Recruiting
AbbVie
Phase 1
127
California, Colorado, Florida, Georgia, Illinois, Michigan
2026-02-27
Recruiting
Nuvaira, Inc.
Not applicable
200
Alabama, Florida, Michigan, North Carolina, Ohio, Pennsylvania, Virginia, Wisconsin
2026-02-24
Recruiting
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
IDEAYA Biosciences
Phase 1
150
California, Colorado, Connecticut, Florida, Michigan, New Jersey, New York, Tennessee
2026-02-24
Recruiting
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
NCT07189871Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
Radiopharm Theranostics, Ltd
Phase 1/2
61
Alabama, Michigan, Nebraska, Texas
2026-02-23
Recruiting
Galderma R&D
Phase 2
162
Michigan, Texas
2026-02-20
Recruiting
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
NCT07425574Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
Astellas Pharma Global Development, Inc.
Observational
90
Arizona, California, Florida, Illinois, Michigan, Mississippi, North Carolina, Ohio
2026-02-20
Recruiting
Elevara Medicines Limited
Phase 2
180
Arizona, California, Colorado, Florida, Louisiana, Michigan, North Carolina, Pennsylvania
2026-02-18
Recruiting
Crescent Biopharma, Inc.
Phase 1/2
540
Alabama, California, Colorado, District of Columbia, Florida, Michigan, New York, Ohio
2026-02-17
Recruiting
Electra Therapeutics Inc.
Phase 1
84
Connecticut, Georgia, Michigan, New York, Ohio, Texas
2026-02-17
Not yet open
Clinical Evaluation of Radiation Reduction for Optimized Safety
NCT06348875Coronary Artery Disease, Myocardial Infarction, Coronary Disease, Coronary Stenosis
Angiowave Imaging
Observational
50
Michigan
2026-02-15
Recruiting
Aspiration Thrombectomy Using the Symphony or Prodigy System
NCT07350499Arterial Thromboembolism, Venous Thromboembolism, Pulmonary Embolism
Imperative Care, Inc.
Observational
750
Alabama, Florida, Illinois, Indiana, Michigan, New York, North Carolina, Ohio
2026-02-13
Recruiting
Elion Therapeutics, Inc.
Phase 2
60
Alabama, California, Georgia, Maryland, Massachusetts, Michigan, Missouri, Texas
2026-02-13
Recruiting
Rivus Pharmaceuticals, Inc.
Phase 2
180
Arizona, Arkansas, California, Florida, Illinois, Louisiana, Michigan, Minnesota
2026-02-13
Recruiting
GlaxoSmithKline
Phase 1/2
54
California, Michigan, Pennsylvania, Utah
2026-02-10
Recruiting
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
NCT07201922Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
80
California, Colorado, Florida, Kansas, Massachusetts, Michigan, Minnesota, New York
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
800
Alabama, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan
2026-02-10
Recruiting
AstraZeneca
Phase 2
124
Arizona, California, Kansas, Maryland, Massachusetts, Michigan, New York, North Carolina
2026-02-10
Recruiting
Viatris Innovation GmbH
Phase 3
300
Florida, Michigan, Texas
2026-02-09
Recruiting
Neurocrine Biosciences
Phase 2
100
Arkansas, California, Florida, Georgia, Illinois, Michigan, Missouri, Nebraska
2026-02-06
Active, closed
Corxel Pharmaceuticals
Phase 2
251
Alabama, California, Florida, Georgia, Illinois, Indiana, Maryland, Michigan
2026-02-06
Recruiting
Poisera, Inc.
Not applicable
160
Michigan
2026-02-05
Recruiting
Bristol-Myers Squibb
Phase 1/2
240
Michigan, New York, North Carolina, Ohio, Tennessee
2026-02-03
Recruiting
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
NCT06968845Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics
Phase 2
120
Alabama, California, Colorado, Connecticut, Florida, Indiana, Kansas, Michigan
2026-02-02
Recruiting
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
NCT07422675PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
Serina Therapeutics
Phase 1
40
Colorado, Florida, Michigan, Washington
2026-02-01
Recruiting
OsteoRemedies, LLC
Phase 2
60
Michigan, North Carolina
2026-02-01
Active, closed
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
NCT07363720Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
Takeda
Phase 3
98
California, Florida, Michigan, New Jersey, North Carolina, Ohio, South Carolina, Texas
2026-01-29
Recruiting
Corcept Therapeutics
Phase 2
80
Arizona, California, Florida, Georgia, Indiana, Kansas, Michigan, Minnesota
2026-01-27
Active, closed
Takeda
Phase 2
91
Arizona, Arkansas, California, Florida, Massachusetts, Michigan, New Hampshire, New York
2026-01-26
Recruiting
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
NCT07287917Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Aminex Therapeutics, Inc.
Phase 1/2
92
Arizona, California, Colorado, Kansas, Michigan, Minnesota, New York, Ohio
2026-01-26
Recruiting
IDEAYA Biosciences
Phase 3
520
Arizona, California, Colorado, Florida, Maryland, Massachusetts, Michigan, Minnesota
2026-01-25
Active, closed
Eli Lilly and Company
Phase 3
600
Arizona, California, Florida, Hawaii, Kentucky, Massachusetts, Michigan, New York
2026-01-24
Recruiting
AbbVie
Phase 2
165
Alabama, Florida, Illinois, Michigan, Missouri, Pennsylvania, Virginia
2026-01-23
Recruiting
LB Pharmaceuticals Inc.
Phase 2
320
Arkansas, California, Florida, Georgia, Illinois, Michigan, Missouri, Nevada
2026-01-23
Active, closed
CSL Behring
Phase 2
84
Arizona, California, Florida, Indiana, Louisiana, Maryland, Michigan, Minnesota
2026-01-22
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.
Phase 2/3
153
California, Illinois, Massachusetts, Michigan, Minnesota, New Jersey, New York, Pennsylvania
2026-01-22
Recruiting
Generate Biomedicines
Phase 3
786
California, Florida, Kansas, Massachusetts, Michigan, Missouri, New York, Ohio
2026-01-20
Active, closed
Janssen Research & Development, LLC
Phase 2
189
California, Florida, Illinois, Indiana, Michigan, North Dakota, Oregon, Pennsylvania
2026-01-20
Recruiting
Sanofi
Phase 3
2,195
Arkansas, California, Florida, Kentucky, Michigan, New York, South Carolina, Texas
2026-01-20
Recruiting
DualityBio Inc.
Phase 1/2
127
Florida, Michigan, North Carolina, Ohio
2026-01-20
Recruiting
Corcept Therapeutics
Phase 1/2
50
California, Illinois, Michigan, Texas, Utah
2026-01-16
Recruiting
Cartography Biosciences
Phase 1
80
Arizona, California, Florida, Georgia, Michigan, Texas, Virginia
2026-01-15
Recruiting
Takeda
Phase 3
183
Alabama, California, Kansas, Maryland, Michigan, Missouri, New York
2026-01-14
Recruiting
Stemline Therapeutics, Inc.
Phase 1
100
Arkansas, Connecticut, Florida, Massachusetts, Michigan, Minnesota, Virginia
2026-01-10
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
AstraZeneca
Phase 1/2
27
Arizona, California, Florida, Illinois, Maryland, Michigan, Missouri, New York
2026-01-09
Active, closed
Hoffmann-La Roche
Phase 2
120
California, Florida, Georgia, Michigan, Minnesota, Pennsylvania
2026-01-08
Recruiting
Incyte Corporation
Phase 1
280
California, Michigan, Nebraska, New York, Tennessee, Texas
2026-01-08
Active, closed
Invivyd, Inc.
Phase 3
1,770
California, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2026-01-08
Recruiting
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines, Inc.
Phase 1
574
Connecticut, Maryland, Massachusetts, Michigan, New York, Texas, Virginia
2026-01-08
Recruiting
The ArtixASCEND Study
NCT07135895Acute Lower Limb Arterial Occlusion
Inari Medical
Not applicable
250
California, Connecticut, District of Columbia, Florida, Louisiana, Maryland, Massachusetts, Michigan
2026-01-07
Recruiting
Biogen
Phase 2
81
California, Colorado, Illinois, Kansas, Michigan, Minnesota, Missouri, Nebraska
2026-01-05
Recruiting
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
NCT07282587Advanced Pheochromocytoma and Paraganglioma, PCPG
DrugONC206
Jazz Pharmaceuticals
Phase 2
90
California, Colorado, Michigan, Minnesota, Missouri, New York, Pennsylvania, Utah
2026-01-02
Recruiting
Regeneron Pharmaceuticals
Phase 3
915
Georgia, Michigan, New York, Ohio, Texas
2026-01-02
Recruiting
Xerient Pharma
Phase 1/2
36
California, Michigan, New Mexico, Texas
2026-01-01
Recruiting
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
NCT07361562Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
Cogent Biosciences, Inc.
Phase 1
100
Arizona, Connecticut, Florida, Illinois, Louisiana, Michigan, Minnesota, Missouri
2025-12-30
Active, closed
UCB Biopharma SRL
Phase 2
165
California, Florida, Georgia, Illinois, Indiana, Kentucky, Michigan, Nebraska
2025-12-29
Active, closed
Prime Medicine, Inc.
Observational
30
California, Connecticut, Illinois, Massachusetts, Michigan, Texas
2025-12-29
Recruiting
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
NCT07333183Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases
Pulmovant, Inc.
Phase 2
20
California, Florida, Illinois, Kansas, Massachusetts, Michigan, New Mexico, North Carolina
2025-12-23
Recruiting
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
NCT07110454Epilepsy, Epilepsy (Treatment Refractory)
Epiminder America, Inc.
Observational
210
Alabama, Arizona, California, Connecticut, Florida, Indiana, Massachusetts, Michigan
2025-12-23
Recruiting
Diagnosing Epilepsy To EffeCT Change
NCT07110337Epilepsy, Epilepsy (Treatment Refractory)
Epiminder America, Inc.
Not applicable
210
Alabama, Arizona, California, Connecticut, Florida, Indiana, Massachusetts, Michigan
2025-12-23
Recruiting
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
NCT07318805Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
Pfizer
Phase 1
260
California, Michigan, New York, Texas, Utah
2025-12-23
Recruiting
Protalix
Phase 2
150
Arizona, Arkansas, California, Florida, Georgia, Michigan, Pennsylvania, Texas
2025-12-22
Recruiting
Tyra Biosciences, Inc
Phase 2
285
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2025-12-22
Recruiting
Eli Lilly and Company
Phase 1
41
Connecticut, Massachusetts, Michigan, New York
2025-12-22
Recruiting
Taiho Oncology, Inc.
Phase 3
360
Alaska, California, District of Columbia, Florida, Georgia, Illinois, Michigan, New Jersey
2025-12-22
Recruiting
argenx
Observational
70
California, Florida, Massachusetts, Michigan, Nevada, New York, North Carolina, Ohio
2025-12-19
Recruiting
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
NCT07444814Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent
Whitehawk Therapeutics, Inc.
Phase 1
226
Alabama, Arizona, Arkansas, California, Illinois, Maryland, Michigan, New Jersey
2025-12-19
Recruiting
argenx
Phase 2
70
California, Florida, Massachusetts, Michigan, Nevada, New York, North Carolina, Ohio
2025-12-19
Recruiting
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
NCT07300241Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic
Neomorph, Inc
Phase 1
30
California, Connecticut, Florida, Illinois, Michigan, Missouri, Nebraska, New York
2025-12-19
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
570
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan, Missouri
2025-12-18
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
California, Colorado, Illinois, Michigan, New York, Ohio, Pennsylvania, Texas
2025-12-17
Recruiting
Hummingbird Bioscience
Phase 1/2
180
California, Indiana, Michigan, Texas
2025-12-17
Recruiting
Ottimo Pharma Limited
Phase 1/2
170
Connecticut, Massachusetts, Michigan, Texas, Utah
2025-12-17
Active, closed
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
NCT07246590Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
302
Florida, Idaho, Indiana, Louisiana, Maryland, Michigan, Nebraska, Nevada
2025-12-17
Recruiting
A Long-term Follow-up Study in Patients Who Received BEAM-101
NCT07373639Hemoglobinopathy, Sickle Cell Disease
Beam Therapeutics Inc.
Observational
50
Alabama, Arizona, Florida, Georgia, Massachusetts, Michigan, Minnesota, Missouri
2025-12-15
Recruiting
Medtronic Neurovascular Clinical Affairs
Observational
118
Florida, Georgia, Illinois, Indiana, Iowa, Michigan, Missouri, New York
2025-12-12
Recruiting
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
NCT07293754Advanced Malignant Solid Tumor
Repertoire Immune Medicines
Phase 1/2
150
Michigan, New York, Texas
2025-12-12
Recruiting
Merck Sharp & Dohme LLC
Phase 2
180
Florida, Michigan, Missouri, New Jersey, New York, Ohio, Oregon, Tennessee
2025-12-12
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.
Phase 3
150
California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Minnesota
2025-12-11
Recruiting
SPIRE Therapeutics Inc.
Not applicable
180
Michigan, Minnesota, Missouri, New York, Pennsylvania, Utah, West Virginia
2025-12-11
Recruiting
SciTech Development, Inc.
Phase 1
44
California, Michigan
2025-12-11
Recruiting
UCB Biopharma SRL
Phase 1
392
Arizona, California, Colorado, Florida, Illinois, Michigan, New Jersey, New Mexico
2025-12-10
Recruiting
ALX Oncology Inc.
Phase 2
120
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Michigan, Minnesota
2025-12-10
Recruiting
Mabylon AG
Phase 1
56
Arkansas, Colorado, Florida, Massachusetts, Michigan, Texas
2025-12-06
Recruiting
Hoffmann-La Roche
Phase 2
160
Arizona, California, Florida, Illinois, Kentucky, Louisiana, Michigan, New York
2025-12-05
Recruiting
Ipsen
Phase 1/2
114
Connecticut, Michigan, Pennsylvania, Texas, Virginia
2025-12-05
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
Maryland, Michigan, Nevada, New Jersey, Utah, Virginia
2025-12-04
Recruiting
Generate Biomedicines
Phase 3
786
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-12-03
Active, closed
Ventus Therapeutics U.S., Inc.
Phase 2
24
California, Florida, Indiana, Michigan, Missouri, New Mexico, New York, Tennessee
2025-12-03
Recruiting
Daiichi Sankyo
Phase 1
60
California, Massachusetts, Michigan, New York, South Carolina, Texas, Virginia, Wisconsin
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
650
Arizona, California, Florida, Georgia, Maryland, Massachusetts, Michigan, Minnesota
2025-12-02
Recruiting
AbbVie
Phase 2
100
California, Connecticut, Florida, Illinois, Michigan, New York, North Carolina, Tennessee
2025-12-01
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Alabama, Arizona, California, Florida, Indiana, Michigan, Minnesota, Nebraska
2025-11-27
Recruiting
Jazz Pharmaceuticals
Phase 1
100
Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Michigan
2025-11-26
Active, closed
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
NCT07129252SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Crinetics Pharmaceuticals Inc.
Phase 1/2
150
Arizona, California, Colorado, Connecticut, Georgia, Kentucky, Louisiana, Michigan
2025-11-26
Active, closed
Kymera Therapeutics, Inc.
Phase 2
200
Alabama, Arkansas, California, Florida, Illinois, Michigan, New York, North Dakota
2025-11-24
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 1/2
152
Arizona, California, Florida, Maryland, Michigan, Minnesota, Ohio, Rhode Island
2025-11-24
Recruiting
The RADIANCE CED Study
NCT07231757Hypertension, Cardiovascular Diseases, Vascular Diseases
ReCor Medical, Inc.
Observational
1,000
Michigan
2025-11-21
Recruiting
Neurotech Pharmaceuticals
Phase 4
234
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-21
Recruiting
Bayer
Phase 3
111
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2025-11-19
Recruiting
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
NCT07205718Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2
273
California, Connecticut, Florida, Maryland, Michigan, Missouri, Ohio, Oregon
2025-11-19
Recruiting
BioNTech SE
Phase 1/2
245
Colorado, Florida, Michigan, New York
2025-11-18
Recruiting
Sanofi
Observational
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Michigan
2025-11-17
By invitation
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
NCT07218003Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
Rondo Therapeutics
Phase 1
149
California, Connecticut, Michigan, New York, North Carolina, South Carolina, Tennessee, Texas
2025-11-17
Recruiting
UCB Biopharma SRL
Phase 3
320
Alabama, California, Florida, Michigan, Ohio, Oklahoma
2025-11-14
Recruiting
AbbVie
Phase 2
400
California, Florida, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Montana
2025-11-13
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
NCT07217171Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma
EvolveImmune United, Inc
Phase 1
160
California, Connecticut, Georgia, Michigan, New York, North Carolina, Ohio, Pennsylvania
2025-11-13
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-11-12
Recruiting
Neuren Pharmaceuticals Limited
Phase 3
160
Alabama, California, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-12
Recruiting
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
NCT04008121Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
MediBeacon
Early Phase 1
10
Michigan
2025-11-06
Recruiting
AstraZeneca
Phase 2
435
California, Colorado, District of Columbia, Florida, Georgia, Kansas, Michigan, Minnesota
2025-11-06
Active, closed
Bluefin Biomedicine, Inc.
Phase 2/3
210
Arizona, California, Florida, Georgia, Indiana, Kentucky, Louisiana, Michigan
2025-11-03
Active, closed
Takeda
Phase 2
207
Arkansas, California, Florida, Louisiana, Maryland, Michigan, New York, South Carolina
2025-11-03
Recruiting
Eli Lilly and Company
Phase 2
222
Arkansas, Florida, Georgia, Michigan, Missouri, Nevada, New York, South Carolina
2025-11-03
Active, closed
Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07214961Prostate Cancer (CRPC), Metastatic Castrate Resistant Prostate Cancer (mCRPC)
ARTBIO Inc.
Phase 1
80
Michigan, Nebraska, New Jersey
2025-11-03
Recruiting
EBR Systems, Inc.
Observational
320
Arizona, Arkansas, Florida, Michigan, Missouri, New York, Ohio, Pennsylvania
2025-11-03
Recruiting
CCM OPEN HF Registry
NCT07112924Heart Failure
Impulse Dynamics
Observational
5,500
Arizona, Florida, Kansas, Massachusetts, Michigan, Minnesota, Missouri, New Hampshire
2025-11-01
Recruiting
Eli Lilly and Company
Phase 3
1,205
Alabama, Arizona, California, Colorado, Florida, Indiana, Maryland, Michigan
2025-10-31
Recruiting
Pfizer
Phase 2
200
Arizona, Arkansas, California, Colorado, Illinois, Maryland, Michigan, New York
2025-10-30
By invitation
Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
NCT07287163Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
Praxis Precision Medicines
Phase 3
700
Florida, Louisiana, Maryland, Michigan, Missouri, New Jersey, New York, Pennsylvania
2025-10-27
Recruiting
Takeda
Phase 3
70
Arizona, California, Illinois, Michigan, New Jersey, New York, Ohio, Oklahoma
2025-10-27
Recruiting
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
NCT07211178Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer
Tempus AI
Observational
900
Alabama, California, Florida, Illinois, Indiana, Michigan, Missouri, Nevada
2025-10-27
Recruiting
Sanofi
Phase 3
60
California, District of Columbia, Illinois, Louisiana, Massachusetts, Michigan, Minnesota, New York
2025-10-24
Active, closed
HEAL-4: Real-World Effectiveness of 4 Amniotic Allografts Adjunctive to Standard Care in DFU, VLU, and PU
NCT07223515Diabetic Foot Ulcer (DFU), Venous Leg Ulcers (VLUs), Pressure Ulcers, Bedsores, Decubitus Ulcer
Dynamic Medical Services dba Acesso Biologics
Observational
2,000
Michigan, Tennessee
2025-10-24
Recruiting
Pulse Biosciences, Inc.
Not applicable
135
California, Florida, Michigan
2025-10-23
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
Eli Lilly and Company
Phase 1
340
California, Florida, Indiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2025-10-22
Recruiting
Ankyra Therapeutics, Inc
Phase 1
60
Florida, Illinois, Indiana, Michigan, Minnesota, New York, North Carolina, Pennsylvania
2025-10-22
Recruiting
Biosense Webster, Inc.
Not applicable
276
Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas, Michigan
2025-10-21
Recruiting
A Study of ZW251 in Participants With Advanced Solid Tumors
NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
Zymeworks BC Inc.
Phase 1
140
California, Kentucky, Michigan, New Jersey, New York, Texas
2025-10-21
Recruiting
GlaxoSmithKline
Phase 1/2
47
Colorado, Michigan, Ohio, Tennessee
2025-10-20
Recruiting
Virtue® SAB in the Treatment of Coronary ISR Trial
NCT07045194Coronary Artery Disease
Orchestra BioMed, Inc
Not applicable
740
Arizona, Florida, Georgia, Indiana, Kansas, Maryland, Massachusetts, Michigan
2025-10-20
Active, closed
Galderma R&D
Phase 2
50
Alabama, Arizona, California, Florida, Indiana, Kentucky, Maryland, Michigan
2025-10-20
Recruiting
Evaluating the Durability of Closure for Diabetic Foot Ulcers Following a Randomized, Controlled, Modified Platform Trial.
NCT07360418Diabetic Foot Ulcers (DFU), Foot Ulcer Chronic, Ulcer, Diabetic Foot Ulcer
Applied Biologics, LLC
Observational
50
Michigan
2025-10-16
Recruiting
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
NCT07006727Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
Novartis Pharmaceuticals
Phase 1
116
Iowa, Massachusetts, Michigan, Washington
2025-10-16
Recruiting
ImmunityBio, Inc.
Phase 1/2
40
Arizona, California, Georgia, Michigan, New York, Pennsylvania, Tennessee, Virginia
2025-10-15
Recruiting
Vega Therapeutics, Inc
Phase 3
60
Arkansas, California, Connecticut, Georgia, Michigan, Minnesota, North Carolina, Pennsylvania
2025-10-15
Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
NCT07174583Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
IDEAYA Biosciences
Phase 1/2
262
Colorado, Florida, Indiana, Michigan, New York, Pennsylvania, Tennessee, Texas
2025-10-14
Active, closed
Merck Sharp & Dohme LLC
Phase 2
185
Arizona, California, Colorado, Florida, Illinois, Michigan, Missouri, Nebraska
2025-10-08
Recruiting
Bristol-Myers Squibb
Observational
223
California, Florida, Georgia, Illinois, Maryland, Michigan, Montana, New Jersey
2025-10-08
Recruiting
Imbria Pharmaceuticals, Inc.
Phase 2
165
California, District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-10-06
Recruiting
Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD
NCT03836482Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome
SeaStar Medical
Not applicable
20
Michigan
2025-10-02
Recruiting
AllRock Bio, Inc.
Phase 2
40
Arizona, California, Colorado, District of Columbia, Florida, Kansas, Michigan, Ohio
2025-10-01
Active, closed
Study of COYA 302 for the Treatment of ALS
NCT07161999Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics
Phase 2/3
120
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-10-01
Recruiting
AstraZeneca
Phase 1/2
283
Arkansas, California, Maryland, Massachusetts, Michigan, New York, Rhode Island, South Carolina
2025-10-01
Recruiting
AstraZeneca
Phase 1/2
52
Florida, Massachusetts, Michigan, New York, Rhode Island
2025-09-30
Recruiting
Eli Lilly and Company
Phase 3
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Michigan, Pennsylvania
2025-09-30
Recruiting
IVUS CHIP UPP Registry
NCT06625801Coronary Artery Disease, Coronary Artery Disease Risk High, Complex Coronary Artery Disease
ECRI bv
Observational
1,010
Arizona, California, Florida, Georgia, Illinois, Kentucky, Michigan, Minnesota
2025-09-30
Recruiting
TLN-372 in Advanced KRAS Mutant Solid Tumors
NCT07204340KRAS Mutant Solid Tumors
Treeline Biosciences, Inc.
Phase 1
270
Alabama, Massachusetts, Michigan, Missouri, New York, Tennessee
2025-09-29
Recruiting
Daiichi Sankyo
Phase 2/3
630
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-09-26
Recruiting
Sanofi
Phase 3
124
California, Florida, Georgia, Massachusetts, Michigan, Minnesota, New York, North Carolina
2025-09-26
Active, closed
Real-World Effectiveness of Amniotic Membrane Allografts Versus Standard Wound Care in DFU, VLU, and PU
NCT07223281Diabetic Foot Ulcer (DFU), Venous Leg Ulcers (VLUs), Pressure Ulcers, Bedsores, Decubitus Ulcer
Legacy Medical Consultants
Observational
2,400
Colorado, Michigan, Oklahoma, West Virginia
2025-09-25
Recruiting
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
NCT07136779Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc
Phase 1/2
310
Michigan, Texas, Utah, Virginia
2025-09-23
Recruiting
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
NCT07141706Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1
253
California, Michigan, Pennsylvania, Texas, Virginia
2025-09-23
Recruiting
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
NCT07140016Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
Astellas Pharma Global Development, Inc.
Phase 1
40
California, Colorado, Georgia, Illinois, Michigan, Missouri, New Jersey, Texas
2025-09-22
Active, closed
W.L.Gore & Associates
Not applicable
112
Alabama, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-09-22
Recruiting
BioNTech SE
Phase 1/2
880
California, Connecticut, District of Columbia, Florida, Massachusetts, Michigan, New York, Ohio
2025-09-22
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas
2025-09-22
Recruiting
Zydus Therapeutics Inc.
Phase 2
240
California, Connecticut, Florida, Georgia, Massachusetts, Michigan, Nebraska, North Carolina
2025-09-17
Recruiting
Kumquat Biosciences Inc.
Phase 1
78
California, Colorado, Florida, Michigan, Ohio, Texas, Utah, Virginia
2025-09-16
Recruiting
Sanofi
Phase 3
942
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Michigan
2025-09-16
Recruiting
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
NCT07047144Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3
Scholar Rock, Inc.
Phase 2
52
Arizona, California, Colorado, Georgia, Iowa, Michigan, Pennsylvania, Texas
2025-09-15
Active, closed
A Study in Subjects With Neurogenic Orthostatic Hypotension
NCT07089043Neurogenic Orthostatic Hypotension
CuraSen Therapeutics, Inc.
Phase 2
12
Arizona, Michigan, New Jersey, New York, Tennessee
2025-09-12
Recruiting
LEO Pharma
Phase 2
135
California, Georgia, Michigan, New York, Ohio, Oregon, Pennsylvania
2025-09-11
Recruiting
Pfizer
Phase 3
140
California, Colorado, District of Columbia, Florida, Illinois, Indiana, Maryland, Michigan
2025-09-10
Recruiting
Bristol-Myers Squibb
Phase 2
182
Alaska, Massachusetts, Michigan, Missouri, New York, Ohio, Oregon, Washington
2025-09-09
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
NCT06689839Aortic Stenosis Treated With TAVI, Aortic Diseases
EnCompass Technologies, Inc.
Not applicable
500
Florida, Indiana, Michigan, Missouri, New York, Ohio, Virginia
2025-09-09
Recruiting
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
NCT07145255Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell)
MBrace Therapeutics
Phase 1/2
150
California, Michigan, New Jersey, Texas, Utah, Virginia
2025-09-03
Recruiting
Neuspera Medical, Inc.
Not applicable
116
California, Florida, Indiana, Kansas, Kentucky, Louisiana, Michigan, Minnesota
2025-09-03
Recruiting
Microvascular Obstruction Diagnosis Using the CoFI™ System Assessment - II
NCT06909578Microvascular Obstruction (MVO), STEMI - ST Elevation Myocardial Infarction, PPCI
CorFlow Therapeutics AG
Not applicable
236
California, Delaware, Illinois, Michigan, Minnesota, New York, North Carolina, Ohio
2025-09-01
By invitation
Lexeo Therapeutics
Observational
10
Michigan
2025-08-29
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Arizona, Arkansas, California, Colorado, Florida, Maryland, Michigan, Missouri
2025-08-28
Recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)
ADARx Pharmaceuticals, Inc.
Phase 2
85
Florida, Iowa, Louisiana, Michigan, New York, Ohio, South Dakota, Texas
2025-08-28
Recruiting
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT07030257Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC)
Tasca Therapeutics
Phase 1/2
150
Colorado, Florida, Michigan, Missouri, Nebraska, North Carolina, Ohio, Pennsylvania
2025-08-27
Recruiting
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
NCT06966024Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
Deciphera Pharmaceuticals, LLC
Phase 1
60
Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Tennessee, Texas
2025-08-27
Recruiting
Basilea Pharmaceutica
Phase 3
234
Alabama, California, Florida, Illinois, Kentucky, Maryland, Michigan, Minnesota
2025-08-26
Recruiting
Vivonics, Inc.
Not applicable
32
Michigan
2025-08-22
Recruiting
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT07020117Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer
Aktis Oncology, Inc.
Phase 1
150
California, Florida, Iowa, Kansas, Maryland, Michigan, New York, Pennsylvania
2025-08-22
Recruiting
Sanofi
Phase 3
90
Arizona, California, Connecticut, District of Columbia, Florida, Louisiana, Massachusetts, Michigan
2025-08-18
Recruiting
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
NCT07085091NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
ALX Oncology Inc.
Phase 1
170
California, Florida, Michigan, New Jersey, Ohio, Oregon, Texas, Utah
2025-08-18
Recruiting
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT07081646Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
Alexion Pharmaceuticals, Inc.
Phase 1/2
91
Arizona, California, Florida, Massachusetts, Michigan, Minnesota, Missouri, New York
2025-08-18
Recruiting
Exelixis
Phase 1
150
Arkansas, California, District of Columbia, Florida, Michigan, New Jersey, North Carolina, Texas
2025-08-18
Recruiting
Thermoacoustic Method for Estimating Liver Fat Fraction
NCT07321925MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Fatty Liver Disease, Nonalcoholic
Endra Lifesciences
Observational
49
Michigan
2025-08-15
Recruiting
Janus II Feasibility
NCT06556693Sleep Apnea
Zoll Medical Corporation
Not applicable
40
Arizona, Michigan, Ohio, Texas
2025-08-12
Recruiting
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT07096674Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
DrugORX750
Centessa Pharmaceuticals (UK) Limited
Phase 2
90
Alabama, California, Florida, Georgia, Michigan, Nevada, North Carolina, Ohio
2025-08-12
Recruiting
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
NCT06927739Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease
Abcentra
Phase 2
240
California, Florida, Indiana, Kentucky, Maryland, Michigan
2025-08-11
Active, closed
AstraZeneca
Phase 3
212
California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Mississippi
2025-08-07
Recruiting
Corteria Pharmaceuticals
Phase 2
210
Indiana, Michigan, North Carolina, Ohio, Oklahoma
2025-08-07
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
California, Florida, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania
2025-08-06
Recruiting
OM336 in Autoimmune Cytopenias
NCT07083960AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia
Lakefront Biotherapeutics West LLC
Phase 1
32
California, District of Columbia, Michigan, Washington
2025-08-01
Recruiting
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
NCT06298916Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
Lantheus Medical Imaging
Phase 1/2
26
California, Michigan, Ohio
2025-08
Active, closed
Pfizer
Phase 3
208
California, Colorado, District of Columbia, Florida, Illinois, Indiana, Maryland, Michigan
2025-07-31
Active, closed
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
SystImmune Inc.
Phase 1
160
Arizona, California, Colorado, Connecticut, Louisiana, Michigan, New Jersey, Tennessee
2025-07-30
Recruiting
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
NCT07024693Fuchs Endothelial Corneal Dystrophy, Fuchs
Design Therapeutics, Inc.
Phase 2
70
Indiana, Michigan
2025-07-30
Recruiting
Study of BHV-1400 in IgA Nephropathy
NCT07054684IgA Nephropathy
Biohaven Therapeutics Ltd.
Phase 1
20
Connecticut, Florida, Georgia, Illinois, Indiana, Michigan, Missouri, South Dakota
2025-07-30
Recruiting
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT07115043Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
AstraZeneca
Phase 1/2
120
Michigan, Missouri, Pennsylvania, Texas, Virginia
2025-07-29
Recruiting
Reprieve Cardiovascular, Inc
Not applicable
400
California, Florida, Georgia, Illinois, Kansas, Kentucky, Michigan, Minnesota
2025-07-28
Recruiting
CSL Behring
Phase 3
20
California, Florida, Georgia, Michigan, Tennessee
2025-07-28
Recruiting
ELEVATE High-Risk PCI Pivotal Study
NCT07001332High-Risk Percutaneous Coronary Intervention (High-risk PCI)
Magenta Medical Ltd.
Not applicable
290
Arizona, California, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan
2025-07-25
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Astellas Pharma Inc
Phase 1
404
California, Georgia, Louisiana, Michigan, Missouri, New Jersey, New York, Ohio
2025-07-25
Not yet open
Asklepion Pharmaceuticals, LLC
Phase 3
120
District of Columbia, Florida, Georgia, Maryland, Michigan, North Carolina
2025-07-25
Recruiting
Windward Bio
Phase 2
600
California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska
2025-07-24
Recruiting
AbbVie
Phase 1/2
325
California, Connecticut, Massachusetts, Michigan, New York, North Carolina, Oregon, Texas
2025-07-23
Recruiting
FoRx Therapeutics AG
Phase 1
40
California, Michigan, Missouri, Oregon, Texas, Virginia
2025-07-22
Active, closed
Compugen Ltd
Phase 1/2
60
Georgia, Illinois, Massachusetts, Michigan, New York, North Carolina, Ohio, Oklahoma
2025-07-21
Recruiting
Bristol-Myers Squibb
Phase 3
586
California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan, Mississippi
2025-07-21
Active, closed
Oruka Therapeutics, Inc.
Phase 2
80
California, Connecticut, Florida, Illinois, Kentucky, Maryland, Massachusetts, Michigan
2025-07-18
Recruiting
Teleflex
Not applicable
150
California, Kansas, Massachusetts, Michigan, Missouri, New York, Texas, West Virginia
2025-07-18
Recruiting
AstraZeneca
Phase 2
100
Delaware, District of Columbia, Kansas, Michigan, New York, Pennsylvania
2025-07-17
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
Nuvalent Inc.
Phase 3
450
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri
2025-07-17
Recruiting
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT06974110Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
MOMA Therapeutics
Phase 1
132
Arizona, California, Florida, Michigan, Missouri, North Carolina, Oregon, Texas
2025-07-16
Recruiting
Bristol-Myers Squibb
Phase 3
426
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2025-07-16
Recruiting
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
NCT07017933Renal Impairment After Cardiac Surgery, Renal Impairment, Acute Kidney Injury
3ive Labs
Not applicable
124
Florida, Michigan, North Carolina, Ohio
2025-07-16
Active, closed
Bluefin Biomedicine, Inc.
Phase 2
225
Arizona, California, Florida, Georgia, Indiana, Louisiana, Massachusetts, Michigan
2025-07-15
Recruiting
Apreo Health, Inc.
Not applicable
250
Alabama, Arizona, California, Florida, Illinois, Kansas, Massachusetts, Michigan
2025-07-15
Recruiting
Abiomed Inc.
Observational
350
Arkansas, California, Florida, Hawaii, Illinois, Massachusetts, Michigan, Minnesota
2025-07-10
Recruiting
Bristol-Myers Squibb
Phase 3
426
Arizona, California, Colorado, Florida, Louisiana, Maryland, Massachusetts, Michigan
2025-07-10
Recruiting
CSL Behring
Phase 2
70
California, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-07-10
Recruiting
Imunon
Phase 3
500
Florida, Louisiana, Michigan, Minnesota, Missouri, New York, Oregon, South Dakota
2025-07-09
Recruiting
XyloCor Therapeutics, Inc.
Phase 2
106
Alabama, Arizona, Georgia, Massachusetts, Michigan, Minnesota, New York, North Carolina
2025-07-08
Active, closed
Novartis Pharmaceuticals
Phase 2
168
California, Colorado, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-07-07
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
360
California, District of Columbia, Michigan, New York, Pennsylvania, Tennessee, Washington
2025-07-03
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Arizona, California, Connecticut, Kansas, Michigan, New York, North Carolina, Ohio
2025-07-02
Not yet open
GyroGlove Use in Essential Tremor Patients
NCT05958030Essential Tremor
GyroGear Ltd
Not applicable
30
Michigan, Texas, Vermont
2025-07
Recruiting
Ipsen
Phase 2
132
Arizona, California, Florida, Georgia, Illinois, Michigan, New York, Washington
2025-06-30
Recruiting
Pulmotect, Inc.
Phase 2
100
California, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York
2025-06-27
Recruiting
Novo Nordisk A/S
Phase 2
200
Alabama, Arizona, California, Colorado, Florida, Kentucky, Michigan, Minnesota
2025-06-27
Recruiting
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
Verastem, Inc.
Phase 1/2
616
California, Maryland, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Tennessee
2025-06-24
Recruiting
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
NCT07082803Lymphoma, Lymphoma, Non Hodgkin
Treeline Biosciences, Inc.
Phase 1
180
California, Michigan, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-06-23
Recruiting
AbbVie
Phase 2
180
Arizona, Arkansas, California, Colorado, Florida, Illinois, Louisiana, Michigan
2025-06-20
Recruiting
GlaxoSmithKline
Phase 3
981
California, Delaware, Florida, Georgia, Illinois, Maryland, Michigan, Missouri
2025-06-20
Recruiting
EXACT Therapeutics AS
Phase 2
25
Arizona, California, Massachusetts, Michigan, Pennsylvania, Rhode Island
2025-06-19
Recruiting
AERA Pediatrics Registry
NCT07071298Dysfunction of Eustachian Tube
Integra LifeSciences Corporation
Observational
300
California, Massachusetts, Michigan, Minnesota, Ohio, Pennsylvania, Texas, Utah
2025-06-17
Active, closed
An Observational Study of Individuals With Isolated Dystonia
NCT07111663Isolated/Primary Dystonia That Affects More Than One Region of the Body
Vima Therapeutics
Observational
200
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan
2025-06-17
Recruiting
Suninflam Inc
Phase 1
88
Arizona, Florida, Hawaii, Maryland, Michigan, New York, North Carolina, Texas
2025-06-16
Recruiting
Biocomposites Ltd
Phase 2
60
Arizona, Illinois, Michigan, Mississippi, Missouri, Nebraska, New Jersey, New York
2025-06-15
Recruiting
PatenSee Ltd.
Observational
90
Michigan
2025-06-06
Recruiting
Celgene
Phase 2
200
Alabama, Arizona, Colorado, Florida, Kansas, Massachusetts, Michigan, Missouri
2025-06-05
By invitation
Virtuos Bone Graft in Lumbar Fusion
NCT06686017Degenerative Disc Disease
Orthofix Inc.
Observational
150
Indiana, Michigan, Montana, North Carolina, South Carolina, Texas, Virginia
2025-06-05
Recruiting
Chugai Pharmaceutical
Phase 1
130
Michigan, Texas, Virginia
2025-06-05
Active, closed
Novo Nordisk A/S
Phase 3
609
California, Florida, Georgia, Illinois, Indiana, Iowa, Michigan, Missouri
2025-06-03
Active, closed
PYC Therapeutics
Phase 1/2
17
Florida, Michigan, Oregon, Texas
2025-06-01
Recruiting
Debiopharm International SA
Phase 1/2
154
California, Florida, Illinois, Michigan, New York, Ohio, Texas
2025-05-30
Active, closed
Syncromune, Inc.
Phase 2
91
Arizona, Arkansas, California, Florida, Illinois, Kansas, Louisiana, Michigan
2025-05-29
Active, closed
Paradigm Biopharmaceuticals Ltd.
Phase 3
466
Arizona, California, Florida, Illinois, Maryland, Michigan, Nebraska, Nevada
2025-05-29
Active, closed
Eli Lilly and Company
Phase 3
586
Arizona, California, Colorado, Florida, Kansas, Louisiana, Massachusetts, Michigan
2025-05-29
Recruiting
Regeneron Pharmaceuticals
Phase 2
397
Alabama, California, Florida, Illinois, Kansas, Kentucky, Massachusetts, Michigan
2025-05-28
Recruiting
AbbVie
Phase 2
110
Florida, Kentucky, Massachusetts, Michigan, Pennsylvania, Texas
2025-05-28
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
50
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2025-05-26
Recruiting
Biogen
Phase 3
180
Alabama, California, Michigan, New York, North Carolina, Ohio, Tennessee, Texas
2025-05-22
Active, closed
Upstream Bio Inc.
Phase 2
396
California, Florida, Idaho, Maryland, Michigan, Nevada, New York, Ohio
2025-05-21
Recruiting
Minima Stent System Post- Approval Study (PAS)
NCT06828770Pulmonary Artery Stenosis, Aortic Coarctation
Renata Medical
Observational
100
California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-05-21
Recruiting
Pfizer
Phase 2
252
Alabama, Arizona, California, Colorado, Georgia, Illinois, Kansas, Michigan
2025-05-20
Recruiting
ARS Pharmaceuticals, Inc.
Phase 4
600
California, District of Columbia, Illinois, Michigan, New York, Ohio
2025-05-20
Active, closed
Eli Lilly and Company
Phase 3
600
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-19
Active, closed
Eli Lilly and Company
Phase 3
800
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Recruiting
Corxel Pharmaceuticals
Phase 2/3
740
California, Colorado, District of Columbia, Florida, Illinois, Kansas, Maryland, Michigan
2025-05-15
Active, closed
Eli Lilly and Company
Phase 3
1,400
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Recruiting
Apogee Therapeutics, Inc.
Phase 2
350
California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan, New York
2025-05-14
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1/2
166
California, Illinois, Michigan, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-05-12
Recruiting
Biogen
Phase 3
454
Arkansas, California, Florida, Georgia, Massachusetts, Michigan, Mississippi, Missouri
2025-05-08
Recruiting
TG Therapeutics, Inc.
Phase 1
100
California, Michigan, Nebraska, New York, Ohio, Wisconsin
2025-05-06
Recruiting
Takeda
Phase 2
88
Alabama, Arizona, California, Colorado, Florida, Georgia, Maryland, Michigan
2025-05-06
Rows per page Showing 1–500 of 1476
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 November 2026. https://priyalifescience.com/clinical-trials-usa/state/michigan

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,148 studies in total at the last sync on 21 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,476 of those studies with a site in Michigan.

How many clinical trials are recruiting in Michigan?

825 of the 1,476 studies on this page are recruiting new participants as of the 21 Nov 2026, 03:16 UTC sync. A further 23 have not yet opened recruitment, 601 are active but closed to new participants, and 27 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Michigan), 1,476 studies
PhaseStudiesRecruitingShare
Phase 333816622.9%
Phase 228915619.6%
Phase 125016716.9%
Phase 1/222214415%
Not applicable1657711.2%
Observational142729.6%
Phase 2/342282.8%
Phase 424141.6%
Early Phase 1410.3%

Most active sponsors

Lead sponsors with the most studies (Michigan)
Lead sponsorStudiesRecruiting
AstraZeneca5022
Eli Lilly and Company4024
Janssen Research & Development, LLC3816
AbbVie3618
Merck Sharp & Dohme LLC3622
Hoffmann-La Roche318
Pfizer3018
Novartis Pharmaceuticals2815
Regeneron Pharmaceuticals2415
Bristol-Myers Squibb2212
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.